Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis
BackgroundTriple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with limited treatment options and poor prognosis. Capecitabine, as a novel adjuvant chemotherapy for TNBCs, remains controversial. Therefore, we conducted this meta-analysis to assess the efficacy and saf...
Main Authors: | Xueqiong Xun, Qinguang Cao, Pan Hong, Saroj Rai, Yeming Zhou, Ruikang Liu, Huiyong Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.899423/full |
Similar Items
-
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
by: Chen Y, et al.
Published: (2024-04-01) -
Clinical pharmacokinetics of capecitabine and its metabolites in colorectal cancer patients
by: Saeed Alqahtani, et al.
Published: (2022-05-01) -
Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
by: Xueqiong Xun, et al.
Published: (2023-01-01) -
Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis
by: Jie Bai, et al.
Published: (2023-10-01) -
Combination of Ixabepilone and Capecitabine in Metastatic Triple Negative Breast Cancer. Clinical case
by: E. V. Glazkova, et al.
Published: (2019-12-01)